The sensor, part of the 510(k) clearance, was developed in partnership with AstraZeneca
MADISON, Wis.-Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to connect patients using the Symbicort Inhaler to its digital health platform.
Propeller’s platform already connects to the majority of inhalers used by asthma and COPD patients, including those manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, as well as many generic equivalent inhalers.
Propeller is a digital health tool that helps people with asthma or COPD manage their condition in partnership with their clinician. Propeller sensors attach to patients’ existing inhalers and deliver insights on medication use to the Propeller app on their smartphone, which patients can then share with their clinician to help inform their treatment plan.
The Propeller platform has been shown in previous clinical studies to increase asthma control by up to 63 percent,1 increase medication adherence by up to 58 percent,2 reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent,3 and reduce COPD-related healthcare utilization by as much as 35 percent.4
“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” said David Van Sickle, co-founder and CEO of Propeller Health. “This is an important step in transforming the way people receive preventative care, enabling self-management from home and ensuring that providers have the bandwidth to focus on high-risk patients.”
1 Merchant RK et al. J Allergy Clin Immunol Pract 2016
2 Van Sickle D et al. Eur Respir J 2016
3 Merchant RK et al. World Allergy Org J 2018
4 Alshabani K et al. J Telemed Telecare 2019
About Propeller Health
Propeller Health is a leading digital health company dedicated to making life better for every person with chronic respiratory disease. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. Propeller Health is a wholly owned subsidiary of ResMed (NYSE: RMD, ASX: RMD). For more information, visit www.propellerhealth.com.